Startseite Evaluation of two HbA1c point-of-care analyzers
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Evaluation of two HbA1c point-of-care analyzers

  • Catalina Sánchez-Mora , Manuel S. Rodríguez-Oliva , Patricia Fernández-Riejos , Joaquín Mateo , Juan Polo-Padillo , Raimundo Goberna und Víctor Sánchez-Margalet EMAIL logo
Veröffentlicht/Copyright: 17. Februar 2011
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: Measurement of HbA1c is the most important parameter to assess glycemic control in diabetic patients. Different point-of-care devices for HbA1c are available. The aim of this study was to evaluate two point-of-care testing (POCT) analyzers (DCA Vantage from Siemens and Afinion from Axis-Shield). We studied the bias and precision as well as interference from carbamylated hemoglobin.

Methods: Bias of the POCT analyzers was obtained by measuring 53 blood samples from diabetic patients with a wide range of HbA1c, 4%–14% (20–130 mmol/mol), and comparing the results with those obtained by the laboratory method: HPLC HA 8160® Menarini. Precision was performed by 20 successive determinations of two samples with low 4.2% (22 mmol/mol) and high 9.5% (80 mmol/mol) HbA1c values. The possible interference from carbamylated hemoglobin was studied using 25 samples from patients with chronic renal failure.

Results: The means of the differences between measurements performed by each POCT analyzer and the laboratory method (95% confidence interval) were: 0.28% (p<0.005) (0.10–0.44) for DCA and 0.27% (p<0.001) (0.19–0.35) for Afinion. Correlation coefficients were: r=0.973 for DCA, and r=0.991 for Afinion. The mean bias observed by using samples from chronic renal failure patients were 0.2 (range –0.4, 0.4) for DCA and 0.2 (–0.2, 0.5) for Afinion. Imprecision results were: CV=3.1% (high HbA1c) and 2.97% (low HbA1c) for DCA, CV=1.95% (high HbA1c) and 2.66% (low HbA1c) for Afinion.

Conclusions: Both POCT analyzers for HbA1c show good correlation with the laboratory method and acceptable precision.


Corresponding author: Víctor Sánchez-Margalet, Clinical Biochemistry Department, Virgen Macarena University Hospital, Av. Dr. Fedriani 3, Seville 41071, Spain

Received: 2010-7-23
Accepted: 2010-11-2
Published Online: 2011-02-17
Published in Print: 2011-04-01

©2011 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Editorial
  2. Nuclear and radiation accidents: the next and further challenge for laboratory diagnostics
  3. Reviews
  4. Diagnostic, prognostic and therapeutic relevance of B-type natriuretic hormone and related peptides in children with congenital heart diseases
  5. Miniaturization and globalization of clinical laboratory activities
  6. Inflammatory markers in childhood asthma
  7. Age-related macular degeneration: genetic and clinical findings
  8. Opinion Paper
  9. Economic evidence in decision-making process in laboratory medicine
  10. Point
  11. A new concept to derive permissible limits for analytical imprecision and bias considering diagnostic requirements and technical state-of-the-art
  12. Counterpoint
  13. Do new concepts for deriving permissible limits for analytical imprecision and bias have any advantages over existing consensus?
  14. Genetics and Molecular Diagnostics
  15. Non-invasive prenatal diagnosis of trisomy 21 by reverse transcriptase multiplex ligation-dependent probe amplification
  16. General Clinical Chemistry and Laboratory Medicine
  17. Evaluation of the Menarini/ARKRAY ADAMS A1c HA-8180V analyser for HbA1c
  18. Evaluation of two HbA1c point-of-care analyzers
  19. Indirect reference intervals of plasma and serum thyrotropin (TSH) concentrations from intra-laboratory data bases from several German and Italian medical centres
  20. Pseudohypocalcemia caused by perchlorate (Irenat®)
  21. Serum cholesterol measured by isotope dilution liquid chromatography tandem mass spectrometry
  22. Confirmation of congenital adrenal hyperplasia by adrenal steroid profiling of filter paper dried blood samples using ultra-performance liquid chromatography-tandem mass spectrometry
  23. Sensitivity and specificity of the high fluorescent lymphocyte count-gate on the Sysmex XE-5000 hematology analyzer for detection of peripheral plasma cells
  24. Clauss assay and fibrinogen protein estimated by capillary zone electrophoresis
  25. High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice
  26. Cancer Diagnostics
  27. Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients
  28. MMP-9 expression in peripheral blood mononuclear cells and the association with clinicopathological features and prognosis of nasopharyngeal carcinoma
  29. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma
  30. Cardiovascular Diseases
  31. B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent’s Screening TO Prevent Heart Failure) study
  32. Elevated concentrations of Nɛ-homocysteinyl-lysine isopeptide in acute myocardial infarction: links with ADMA formation
  33. Letters to the Editor
  34. More on preanalytical variables affecting platelet function testing using light transmittance aggregometry
  35. Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification
  36. Why do different EQA schemes have apparently different limits of acceptability?
  37. Prevalence of antithyroid antibodies and thyroid-stimulating hormone concentration in young people
  38. Evaluation of multiplex PCR using dual-priming oligonucleotide for the detection of vanA and vanB in vancomycin-resistant enterococci
  39. The IFCC Task Force for Young Scientists
Heruntergeladen am 6.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.101/html
Button zum nach oben scrollen